Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma

Cancer Research

Volumn 59, Issue 16, 1999, Pages 3911-3914

  Parthasarathy, Ranjani ^a   Cote, Gilbert J ^a   Gagel, Robert F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOZYME;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CATALYSIS; COLONY FORMATION; GENE MUTATION; GENE TARGETING; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; RNA CLEAVAGE; TARGET CELL; THYROID MEDULLARY CARCINOMA;

3T3 CELLS; ANIMALS; CARCINOMA, MEDULLARY; CELL TRANSFORMATION, NEOPLASTIC; DROSOPHILA PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, CATALYTIC; RNA, MESSENGER; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033566948     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Wohlk, N., Cote, G. J., Evans, D. B., Goepfert, H., Ordonez, N. G., and Gagel, R. F. Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocrinol. Metab. Clin. N. Am., 25: 1-25, 1996.
2. Mulligan, L. M., Kwok, J. B., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., Ponder, M. A., Telenius, H., Tunnacliffe, A., and Ponder, B. A. J. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia 2A. Nature (Lond.), 363: 458-460, 1993.
3. Hofstra, R. M., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W., van Amstel, H. K., Romeo, G., and Ponder, B. A. J. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature (Lond.), 367: 375-376, 1994.
4. Samaan, N. A., Schultz, P. N., and Hickey, R. C. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J. Clin. Endocrinol. Metab., 67: 801-805, 1988.
5. Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Constatini, F., and Pachnis, V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor RET. Nature (Lond.), 367: 380-383, 1994.
6. Xing, S., Smanik, P. A., Oglesbee, M. J., Trosko, J. E., Mazzaferri, E. L., and Jhiang, S. M. Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes. Endocrinology, 137: 1512-1519, 1996.
7. Kashani-Sabet, M., and Scanlon, K. J. Application of ribozymes to cancer gene therapy. Cancer Gene Ther., 2: 212-222, 1995.
8. Hendry, P., McCall, M. J., Santiago, F. S., and Jennings, P. A. In vitro activity of minimized hammerhead ribozymes. Nucleic Acids Res., 23: 3922-3927, 1995.
9. Zillman, M., Limauro S. E., and Goodchild, J. In vitro optimization of truncated stem-loop II variants of the hammerhead ribozyme for cleavage in low magnesium under non-turnover conditions. RNA, 3: 734-747, 1997.
10. Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, M., Kraus, M. H., and Di Fiore, P. P. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (Washington DC), 267: 381-383, 1995.
11. Tsuchida, T., Kijima, H., Oshika, Y., Tokunaga, T., Abe, Y., Yamaoki, N., Ueyama, Y., Scanlon, K. J., and Nakamura, M. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells. Biochem. Biophys. Res. Commun., 253: 368-373, 1998.
12. Wright, L. A., Milliken, S., Biggs, J. C., and Kearney, P. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line. Antisense Nucleic Acid Drug Dev., 8: 15-23, 1998.
13. Yokoyama, Y., Takahashi, Y., Shinohara, A., Lian, A., Wan, X., Niwa, K., and Tamaya, T. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res., 58: 5406-5410, 1998.